nach oben

nächster Artikel Arzneimittelinteraktionen im Überblick

Tipp

Nichtmedikamentöse Therapie von Fettstoffwechselstörungen: Möglichkeiten und Grenzen

Zeitschrift:: Wiener klinische Wochenschrift Education > Ausgabe 1-4/2018

Autoren:: Univ.-Prof. Dr. Christoph H. Saely, Raphael Gansch, Heinz Drexel

» Jetzt Zugang zum Volltext erhalten

Wichtige Hinweise

C.H. Saely und R. Gansch haben zu dieser Arbeit in gleichem Umfang beigetragen.

Ohne Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Jetzt einloggen Kostenlos registrieren

Sie möchten Zugang zu diesem Inhalt erhalten? Dann informieren Sie sich jetzt über unsere Produkte:

Abo für kostenpflichtige Inhalte

Jetzt informieren

WHO. The top 10 causes of death. 2017. http://www.who.int/mediacentre/factsheets/fs310/en/. Zugegriffen: 01.2018

Nemetz PN, Smith CY, Bailey KR, Roger VL, Edwards WD, Leibson CL. Trends in coronary atherosclerosis: a tale of two population subgroups. Am J Med. 2016;129(3):307–14. PubMedCrossRef

Tabas I, Garcia-Cardena G, Owens GK. Recent insights into the cellular biology of atherosclerosis. J Cell Biol. 2015;209(1):13–22. PubMedPubMedCentralCrossRef

Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017; https://doi.org/10.1093/eurheartj/ehx144. PubMedPubMedCentralCrossRef

Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med. 1977;62(5):707–14. PubMedCrossRef

Ference BA, Robinson JG, Brook RD, Catapano AL, Chapman MJ, Neff DR, et al. Variation in PCSK9 and HMGCR and risk of cardiovascular disease and diabetes. N Engl J Med. 2016;375(22):2144–53. PubMedCrossRef

Drexel H, Aczel S, Marte T, Benzer W, Langer P, Moll W, et al. Is atherosclerosis in diabetes and impaired fasting glucose driven by elevated LDL cholesterol or by decreased HDL cholesterol? Diabetes Care. 2005;28(1):101–7. PubMedCrossRef

Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimibe added to Statin therapy after acute coronary syndromes. N Engl J Med. 2015;372(25):2387–97. PubMedCrossRef

Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713–22. PubMedCrossRef

10.

Fruchart JC. Selective peroxisome proliferator-activated receptor alpha modulators (SPPARMalpha): the next generation of peroxisome proliferator-activated receptor alpha-agonists. Cardiovasc Diabetol. 2013;12:82. PubMedPubMedCentralCrossRef

11.

Voight BF, Peloso GM, Orho-Melander M, Frikke-Schmidt R, Barbalic M, Jensen MK, et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet. 2012;380(9841):572–80. PubMedPubMedCentralCrossRef

12.

Drexel H, Aczel S, Marte T, Vonbank A, Saely CH. Factors predicting cardiovascular events in statin-treated diabetic and non-diabetic patients with coronary atherosclerosis. Atherosclerosis. 2010;208(2):484–9. PubMedCrossRef

13.

Adiamah A, Psaltis E, Crook M, Lobo DN. A systematic review of the epidemiology, pathophysiology and current management of hyperlipidaemic pancreatitis. Clin Nutr. 2017; https://doi.org/10.1016/j.clnu.2017.09.028. PubMedCrossRef

14.

Drexel H. Statins, fibrates, nicotinic acid, cholesterol absorption inhibitors, anion-exchange resins, omega-3 fatty acids: which drugs for which patients? Fundam Clin Pharmacol. 2009;23(6):687–92. PubMedCrossRef

15.

Saely CH, Eber B, Pfeiffer KP, Drexel H. Low serum LDL cholesterol in patients with type 2 diabetes: an analysis on two different patient populations. Int J Cardiol. 2010;144(3):394–8. PubMedCrossRef

16.

National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III).. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143–421. CrossRef

17.

Drexel H, Saely CH, Langer P, Loruenser G, Marte T, Risch L, et al. Metabolic and anti-inflammatory benefits of eccentric endurance exercise—a pilot study. Eur J Clin Invest. 2008;38(4):218–26. PubMedCrossRef

18.

Fortson MR, Freedman SN, Webster PD 3rd. Clinical assessment of hyperlipidemic pancreatitis. Am J Gastroenterol. 1995;90(12):2134–9. PubMed

19.

Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, et al. 2016 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J. 2016;37(39):2999–3058. PubMedCrossRef

20.

Schaefer EJ, Gleason JA, Dansinger ML. Dietary fructose and glucose differentially affect lipid and glucose homeostasis. J Nutr. 2009;139(6):1257s–62s. PubMedPubMedCentralCrossRef

21.

Yuan G, Al-Shali KZ, Hegele RA. Hypertriglyceridemia: its etiology, effects and treatment. CMAJ. 2007;176(8):1113–20. PubMedPubMedCentralCrossRef

22.

Kovar J, Zemankova K. Moderate alcohol consumption and triglyceridemia. Physiol Res. 2015;64(Suppl 3):S371–S5. PubMed

23.

Chait A, Brunzell JD. Chylomicronemia syndrome. Adv Intern Med. 1992;37:249–73. PubMed

24.

Wood PD, Stefanick ML, Williams PT, Haskell WL. The effects on plasma lipoproteins of a prudent weight-reducing diet, with or without exercise, in overweight men and women. N Engl J Med. 1991;325(7):461–6. PubMedCrossRef

25.

Harris WS, Ginsberg HN, Arunakul N, Shachter NS, Windsor SL, Adams M, et al. Safety and efficacy of Omacor in severe hypertriglyceridemia. J Cardiovasc Risk. 1997;4(5–6):385–91. PubMed

26.

Harris WS, Connor WE, Illingworth DR, Rothrock DW, Foster DM. Effects of fish oil on VLDL triglyceride kinetics in humans. J Lipid Res. 1990;31(9):1549–58. PubMed

27.

Kontush A. HDL-mediated mechanisms of protection in cardiovascular disease. Cardiovasc Res. 2014;103(3):341–9. PubMedCrossRef

28.

Hernaez A, Fernandez-Castillejo S, Farras M, Catalan U, Subirana I, Montes R, et al. Olive oil polyphenols enhance high-density lipoprotein function in humans: a randomized controlled trial. Arterioscler Thromb Vasc Biol. 2014;34(9):2115–9. PubMedCrossRef

29.

Estruch R, Ros E, Salas-Salvado J, Covas MI, Corella D, Aros F, et al. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med. 2013;368(14):1279–90. PubMedCrossRef

30.

Guasch-Ferre M, Hu FB, Martinez-Gonzalez MA, Fito M, Bullo M, Estruch R, et al. Olive oil intake and risk of cardiovascular disease and mortality in the PREDIMED Study. BMC Med. 2014;12:78. PubMedPubMedCentralCrossRef

31.

Patrick L, Uzick M. C‑reactive protein and the inflammatory disease paradigm: HMG-CoA reductase inhibitors, alpha-tocopherol, red yeast rice, and olive oil polyphenols. A review of the literature. Alternative medicine review : a journal of clinical therapeutic. Cardiovasc Dis. 2001;6(3):248–71.

32.

Lu Z, Kou W, Du B, Wu Y, Zhao S, Brusco OA, et al. Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction. Am J Cardiol. 2008;101(12):1689–93. PubMedCrossRef

33.

Nigovic B, Sertic M, Mornar A. Simultaneous determination of lovastatin and citrinin in red yeast rice supplements by micellar electrokinetic capillary chromatography. Food Chem. 2013;138(1):531–8. PubMedCrossRef

34.

Del Gobbo LC, Falk MC, Feldman R, Lewis K, Mozaffarian D. Effects of tree nuts on blood lipids, apolipoproteins, and blood pressure: systematic review, meta-analysis, and dose-response of 61 controlled intervention trials. Am J Clin Nutr. 2015;102(6):1347–56. PubMedPubMedCentralCrossRef

35.

Luo C, Zhang Y, Ding Y, Shan Z, Chen S, Yu M, et al. Nut consumption and risk of type 2 diabetes, cardiovascular disease, and all-cause mortality: a systematic review and meta-analysis. Am J Clin Nutr. 2014;100(1):256–69. PubMedCrossRef

36.

Katan MB, Zock PL, Mensink RP. Trans fatty acids and their effects on lipoproteins in humans. Annu Rev Nutr. 1995;15:473–93. PubMedCrossRef

37.

Brouwer IA, Wanders AJ, Katan MB. Effect of animal and industrial trans fatty acids on HDL and LDL cholesterol levels in humans—a quantitative review. PLoS ONE. 2010;5(3):e9434. PubMedPubMedCentralCrossRef

38.

Brown L, Rosner B, Willett WW, Sacks FM. Cholesterol-lowering effects of dietary fiber: a meta-analysis. Am J Clin Nutr. 1999;69(1):30–42. PubMedCrossRef

39.

Miettinen TA, Puska P, Gylling H, Vanhanen H, Vartiainen E. Reduction of serum cholesterol with sitostanol-ester margarine in a mildly hypercholesterolemic population. N Engl J Med. 1995;333(20):1308–12. PubMedCrossRef

40.

Weingartner O, Lutjohann D, Ji S, Weisshoff N, List F, Sudhop T, et al. Vascular effects of diet supplementation with plant sterols. J Am Coll Cardiol. 2008;51(16):1553–61. PubMedCrossRef

41.

Jenkins DJ, Kendall CW, Marchie A, Faulkner DA, Wong JM, de Souza R, et al. Effects of a dietary portfolio of cholesterol-lowering foods vs lovastatin on serum lipids and C‑reactive protein. JAMA. 2003;290(4):502–10. PubMedCrossRef

42.

Obarzanek E, Sacks FM, Vollmer WM, Bray GA, Miller ER 3rd, Lin PH, et al. Effects on blood lipids of a blood pressure-lowering diet: the Dietary Approaches to Stop Hypertension (DASH) trial. Am J Clin Nutr. 2001;74(1):80–9. PubMedCrossRef

43.

Zeppetzauer M, Drexel H, Vonbank A, Rein P, Aczel S, Saely CH. Eccentric endurance exercise economically improves metabolic and inflammatory risk factors. Eur J Prev Cardiol. 2013;20(4):577–84. PubMedCrossRef

44.

Dehghan M, Mente A, Zhang X, Swaminathan S, Li W, Mohan V, et al. Associations of fats and carbohydrate intake with cardiovascular disease and mortality in 18 countries from five continents (PURE): a prospective cohort study. Lancet. 2017;390(10107):2050–62. PubMedCrossRef

45.

Harvard T.H. Chan, school of public health. PURE study makes headlines, but the conclusions are misleading. 2017. https://www.hsph.harvard.edu/nutritionsource/2017/09/08/pure-study-makes-headlines-but-the-conclusions-are-misleading/;. Zugegriffen: 10. Dez. 2017.

Titel: Nichtmedikamentöse Therapie von Fettstoffwechselstörungen: Möglichkeiten und Grenzen
Autoren:: Univ.-Prof. Dr. Christoph H. Saely
Raphael Gansch
Heinz Drexel
Publikationsdatum: 04.06.2018
Schlagwort: Innere Medizin
DOI: https://doi.org/10.1007/s11812-018-0090-3
Verlag: Springer Vienna
Zeitschrift: Wiener klinische Wochenschrift Education
Ausgabe 1-4/2018
Print ISSN: 1863-3579
Elektronische ISSN: 1863-3765

Springer Medizin Österreich

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Nichtmedikamentöse Therapie von Fettstoffwechselstörungen: Möglichkeiten und Grenzen

Ohne Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Sie möchten Zugang zu diesem Inhalt erhalten? Dann informieren Sie sich jetzt über unsere Produkte:

Abo für kostenpflichtige Inhalte

Das könnte Sie auch interessieren

DFP Fragebogen (PDF)

Neue App: SpringerMed Fortbildung